Prothrombin, Factor-V Leiden, and Plasminogen Activator Inhibitor Type 1 Gene Polymorphisms in Hemodialysis Patients with/without Arteriovenous Fistula Thrombosis

AUTHORS

Elif Funda Emirogullari 1 , * , Cetin Saatci 2 , Aydin Unal 2 , Atilla Sahin 2 , Yusuf Ozkul1 2

1 Erciyes University, Medical Faculty, Department of Medical Genetics, eliffunda@erciyes.edu.tr, TURKEY

2 Department of Medical Genetics, Erciyes University Medical School, Turkey

How to Cite: Emirogullari E, Saatci C, Unal A, Sahin A, Ozkul1 Y. Prothrombin, Factor-V Leiden, and Plasminogen Activator Inhibitor Type 1 Gene Polymorphisms in Hemodialysis Patients with/without Arteriovenous Fistula Thrombosis, Nephro-Urol Mon. Online ahead of Print ; 2(2):314-319.

ARTICLE INFORMATION

Nephro-Urology Monthly: 2 (2); 314-319
Article Type: Research Article
Received: July 8, 2009
Accepted: August 27, 2009

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background and Aims: Factor V Leiden mutation (G1691A) has been recognized to be the most prevalent genetic risk factor for venous thrombosis. Other common risk factor for venous thrombosis is Prothrombin 20210 G-A alteration, which causes a gain of function in the coagulation system with an increase of prothrombin levels, associated with an increased potential to form thrombin. Plasminogen activator inhibitor type 1 (PAI-1) 4G/5G polymorphism is the most frequently studied in thrombotic events. Aim of this study was to investigate the relationship between these polymorphisms and arteriovenous fistula (AVF) thrombosis in hemodialysis (HD) patients.

Methods: The study included 31 HD patients with AVF thrombosis and 51 HD patients without AVF thrombosis. DNA was extracted from peripheral blood samples from the patient and control groups. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods were used to identify the polymorphisms.

Results: There were no significant differences between HD patients with and without AVF thrombosis in terms of Factor V Leiden and Prothrombin G20210A mutations. PAI-1 4G allele in heterozygous state have an effect on the thrombosis risk in HD patients (O.R= 4.271).

Conclusions: Only carrying PAI-1 4G/5G genotype had an additional risk for thrombosis in HD patients.

Keywords

Hemodialysis Factor V Leiden mutation Plasminogen Activator Inhibitor Type 1 4G/5G Polymorphism Prothrombin G20210A Mutation

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: